A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia

Wing, Victoria C.; Wass, Caroline; Soh, Debra W.; George, Tony P.

doi:10.1111/j.1749-6632.2011.06261.x

Cited by 88 publications

(68 citation statements)

References 154 publications

(193 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, we oversampled the control group for smokers. In reality, individuals with schizophrenia might have lower mGluR5 binding than nonpsychotic subjects because they smoke more frequently and more heavily (Wing et al, 2012), although many individuals with schizophrenia do not smoke and we did not find a correlation between the amount of nicotine consumption and mGluR5 DVR. Secondly, our samples were relatively small to demonstrate a negative finding.…”

Section: Discussioncontrasting

confidence: 63%

“…In previous studies, we have demonstrated that smoking is associated with a marked global reduction in mGluR5 DVR (Akkus et al, 2013;Akkus et al, 2015). This is a potentially relevant finding because 60%-90% of individuals with schizophrenia smoke (Chapman et al, 2009), and they usually smoke more heavily and experience more difficulty quitting smoking than do smokers without schizophrenia (Tidey et al, 2005;Wing et al, 2012). This is the first study to assess mGluR5 DVR in subjects with schizophrenia and test for a hypothetical difference in DVR between patients and healthy controls.…”

Section: Introductionmentioning

confidence: 72%

“…The majority of individuals with schizophrenia are smokers and have a smoking cessation rate of 10%-27%, compared with 43% for subjects without psychiatric conditions (Wing et al, 2012). The vulnerability hypothesis proposes that common genetic and environmental factors explain the high comorbidity between schizophrenia and nicotine addiction (Chambers, 2009).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Metabotropic glutamate receptor 5 neuroimaging in schizophrenia

Akkus

Treyer

Ametamey

et al. 2017

Schizophrenia Research

View full text Add to dashboard Cite

The metabotropic glutamate receptor 5 (mGluR5) is a promising drug target for the treatment of schizophrenia. In this study, we compared mGluR5 distribution volume ration (DVR) in subjects with schizophrenia and healthy controls. Given our previous findings, we matched samples for gender, age, and smoking status. Binding to mGluR5 was determined using positron emission tomography and [ 11 C]ABP688, which binds to an allosteric site with high selectivity. DVR in the 15 individuals with schizophrenia did not differ from that of the 15 controls. In both groups, smoking was associated with marked global reductions in mGluR5 availability (on average 23.8%). In nonsmoking subjects with schizophrenia, there was a positive correlation between mGluR5 DVR in the medial orbitofrontal cortex and the use of antipsychotic drugs (r = 0.9, p =0.019). Because antipsychotic drugs such as clozapine appeared to have indirect effects on mGluR5 signaling, our findings may be clinically relevant. They also provide promising leads for elucidating the high comorbidity between schizophrenia and tobacco addiction. Low mGluR5 DVR in smokers my represent a risk factor for schizophrenia. Alternatively, smoking may counteract the potential upregulation of mGluR5 by antipsychotic drugs.

show abstract

Section: Discussioncontrasting

confidence: 63%

Section: Introductionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metabotropic glutamate receptor 5 neuroimaging in schizophrenia

Akkus

Treyer

Ametamey

et al. 2017

Schizophrenia Research

View full text Add to dashboard Cite

show abstract

“…Converging lines of research have focused on the shared vulnerability between nicotine use and schizophrenia, emphasizing the putative dysregulation of nAChR systems in schizophrenia [8,9]. Nicotine is the main psychoactive ingredient in tobacco smoke.…”

Section: The Neurobiology Of Tobacco Addiction In Schizophreniamentioning

confidence: 99%

Translating Neurobiology to the Treatment of Dual Diagnosis: The Example of Nicotinic Receptors and Neurocognitive Endophenotypes in Schizophrenia

et al. 2014

Self Cite

View full text Add to dashboard Cite

Endophenotypes are heritable traits associated with psychiatric illness. Certain endophenotypes associated with schizophrenia such as working memory and sensory gating may be linked to the high tobacco smoking prevalence in patients with schizophrenia. Evidence suggests a critical role for the nicotinic acetylcholine receptor system (nAChR) in the underlying pathophysiology of schizophrenia. Despite the negative consequences associated with tobacco use, patients with schizophrenia have a much more difficult time quitting smoking and remaining abstinent compared with their nonpsychiatric counterparts. Deficits in nAChR function may contribute to the cognitive deficits that are seen with the illness, such as deficits in working memory and sensory gating, and to co-morbid tobacco use disorders. Accordingly, treatments for tobacco use disorder in this population should focus on remediation of the diseaserelated endophenotypes that restore neurocognitive function and reduce the risk of smoking relapse.

show abstract

“…1,2 One factor that may contribute to smoking persistence in this population is the disruptive effects of abstinence on neurocognitive functioning. 3 Cognitive deficits are considered a core feature of schizophrenia 4 and are associated with poor functional outcomes in these patients. 5 Consistent with this theory, experimental studies have found that smoking abstinence impairs attention and spatial working memory performance in smokers with schizophrenia (SS),and smoking reinstatement reverses these impairments.…”

Section: Introductionmentioning

confidence: 99%

Cognitive Effects of Very Low Nicotine Content Cigarettes, With and Without Nicotine Replacement, in Smokers With Schizophrenia and Controls

AhnAllen

Bidwell

Tidey

2014

Nicotine & Tobacco Research

View full text Add to dashboard Cite

Introduction: Beneficial effects of nicotine on cognitive functioning may contribute to the markedly high rates of smoking among people with schizophrenia. A reduction in the nicotine content of cigarettes to non-addictive levels is being considered as a regulatory strategy for reducing tobacco dependence in the United States. We examined whether switching to very low nicotine content (VLNC) cigarettes impairs cognitive functioning in smokers with and without schizophrenia, andwhether nicotine replacement reverses these effects. Methods: Smokers with schizophrenia (SS, n = 29) and control smokers matched on smoking rate but without psychiatric illness (CS, n = 28) smoked usual-brand cigarettes, VLNC cigarettes while wearing 2 placebo patches (PLA), or VLNC cigarettes while wearing 2 nicotine patches totaling 42 mg (NIC) for 5 hr, and then completed computerized assessments of visual sustained attention, motor speed, visual working memory, processing speed, inhibitory control, and response variability. Results: Across conditions, SS were slower than CS in tasks of motor speed and visual working memory, and had poorer target detectability on a visual sustained attention task. Across groups, functioning in domains of visual sustained attention, inhibitory control, processing speed, and response variability was impaired in the VLNC + PLA condition relative to the usual-brand and VLNC + NIC conditions. Conclusions: Dramatically reducing the nicotine content of cigarettes may impair cognitive functioning in heavy smokers with and without schizophrenia, but the use of nicotine replacement while smoking VLNC cigarettes may preserve cognitive functioning in these smokers.

show abstract

A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia

Cited by 88 publications

References 154 publications

Metabotropic glutamate receptor 5 neuroimaging in schizophrenia

Metabotropic glutamate receptor 5 neuroimaging in schizophrenia

Translating Neurobiology to the Treatment of Dual Diagnosis: The Example of Nicotinic Receptors and Neurocognitive Endophenotypes in Schizophrenia

Cognitive Effects of Very Low Nicotine Content Cigarettes, With and Without Nicotine Replacement, in Smokers With Schizophrenia and Controls

Contact Info

Product

Resources

About